In this special report, we asked compound management leaders from Merck, GSK, Genentech and elsewhere to share insight on their main focus areas. Topics discussed: HTS, Controlled Substances, Collaborations, Biologics and Nanotechnology.
|
|
Have Your Say Rate this feature and give us your feedback in the comments section below |
MSD announces Phase III data on investigational treatment to lower LDL Cholesterol (LDL-C)
2025-11-17
AI for Pharma & Healthcare 2025
2025-06-18
April 20-21, 2026
The Logan, Philadelphia, USA
Register Now |
View Agenda |
Learn More